More men at risk for prostate cancer as a result of less regular screening
the ONA take:
A recent research study examined the potential benefits and potential downsides to the US Preventive Services Task Force (USPSTF) recommendation against regular prostate-specific antigen (PSA) screening for prostate cancer.
Researchers, led by Daniel A. Barocas, MD, MPH, of the Department of Urologic Surgery, Vanderbilt University Medical Center, Nashville, Tennessee, examined the number and distribution of new prostate cancer diagnoses in the United States.
Incident cancers diagnosed from January 2010 through December 2012 were included. The number of new prostate cancer cases diagnosed before and after the USPSTF recommendation were compared against a similar record of colon cancer findings.
The investigators found a drop in the number of prostate cancer diagnoses, a greater than 12% decline, following the USPSTF's PSA screening recommendation.
Prostate cancer diagnoses at all risk levels fell, though new diagnoses of nonlocalized disease did not change. Monthly colon cancer diagnoses remained steady before and after the USPSTF recommendation.
One year after the USPSTF recommendation, diagnoses of new low risk cancers dropped by nearly 38%, which does address the USPSTF intent to reduce overdiagnosis, but the researchers have concerns that the reduction in high- and immediate-risk disease diagnoses could lower chances for early detection and treatment.
pThe team feels that additional research into screening models to maximize early detection for higher risk cancers while keeping overdiagnosis and overtreatment numbers low would be beneficial.
Data from this study were published in The Journal of Urology.
A recent study examined the potential benefits and potential downsides to the USPSTF recommendation against regular PSA screening.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Risk for Cardiovascular Disease Higher in Survivors of Testicular Cancer
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|